Thrombocytopenia Study in Patients with Myelodysplastic Syndrome

Principal Investigator: Stephen Medlin, DO

Sub-Investigators: R. Vinod Parameswaran, MD; Kelly McCaul, MD; Addison Tolentino, MD; Mark Huber, MD; Amy Krie, MD; Michael Robinson, MD; Adam Walker, CNP; Tammie Smart, CNP; Kristen Hurley, CNP

Study Coordinator: Jessica Larsen-Gallup

Overview: The purpose of this clinical study is to identify a safe dose of an investigational medication that is appropriate for the treatment of thrombocytopenia in individuals with low or intermediate-1 risk of Myelodysplastic Syndrome (MDS).

The study medication is considered investigational, which means that it has not been approved by the U.S. Food & Drug Administration. In this study, one dose level of the study drug will be tested against placebo (a sugar or salt solution). The sponsor of the study will cover the costs associated with study-specific procedures in this research study that are not part of your routine care.

Inclusion Criteria:

• Men and women between the ages of 18 and 90
• Diagnosis of Myelodysplastic Syndrome

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning to become pregnant
• Previously diagnosed with intermediate-2 or high risk MDS
• Received disease-modifying treatment for MDS
• History of leukemia, aplastic anemia or other non-MDS

Contact:   Erika Meyer

Phone:   (605) 322-3086

Email:    erica.meyer@avera.org